drugset
drugset / Trial / NCT04734990

Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

NCT04734990 ↗

Phase 1/2 Active not recruiting 24 enrolled M.D. Anderson Cancer Center
NaSequentialOpen-labelTreatment

Summary

This phase I/II trial identifies the best dose of seclidemstat when given together with azacitidine in treating patients with myelodysplastic syndrome or chronic myelomonocytic leukemia. Seclidemstat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Azacitidine may help block the formation of growths that may become cancer. Giving seclidemstat and azacytidine may kill more cancer cells.

Timeline

Start
2021-07-07
Primary completion
2027-09-11
Completion
2027-09-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Seclidemstat Small molecule 300 mg Oral
Subject Seclidemstat Small molecule 450 mg Oral
Subject Seclidemstat Small molecule 600 mg Oral
Subject Seclidemstat Small molecule 900 mg Oral
Subject Seclidemstat Small molecule 1200 mg Oral
Subject Seclidemstat Small molecule 1500 mg Oral
Background Azacitidine Other / unclassified — Intravenous

Indications

chronic myelomonocytic leukemia myelodysplastic syndrome